SAIC Announces Third Quarter of Fiscal Year 2020 Results

EBITDA is a performance measure that is calculated by taking net income and excluding interest, provision for income taxes, and depreciation and amortization. Adjusted EBITDA and adjusted operating income are performance measures that exclude acquisition and integration costs that we do not consider to be indicative of our ongoing operating performance. The acquisition and integration costs relate to the Company's significant acquisition of Engility. The recovery of acquisition and integration costs relate to acquisition and integration costs recovered through the Company's indirect rates in accordance with Cost Accounting Standards. We believe that these performance measures provide management and investors with useful information in assessing trends in our ongoing operating performance and may provide greater visibility in understanding the long-term financial performance of the Company.

⁽¹⁾ Non-GAAP measure, see above for definition.

Schedule 5 (continued):
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
NON-GAAP FINANCIAL MEASURES
(Unaudited)

Adjusted Diluted Earnings Per Share
	Three Months Ended						Nine Months Ended
	November 1, 2019			November 2, 2018			November 1, 2019			November 2, 2018
Diluted earnings per share	$	0.94		$	1.11		$	2.82		$	3.37

Acquisition and integration costs, divided by diluted 'weighted-average number of shares outstanding' (WASO)	0.17			0.32			0.41			0.32
Tax effect of acquisition and integration costs, divided by diluted WASO	(0.04		)	(0.06		)	(0.09		)	(0.06		)
Net effect of acquisition and integration costs, divided by diluted WASO	0.13			0.26			0.32			0.26

Amortization of intangible assets, divided by diluted WASO	0.42			0.12			1.23			0.35
Tax effect of amortization of intangible assets, divided by diluted WASO	(0.10		)	(0.02		)	(0.27		)	(0.06		)
Net effect of amortization of intangible assets, divided by diluted WASO	0.32			0.10			0.96			0.29

Adjusted diluted earnings per share ⁽¹⁾	$	1.39		$	1.47		$	4.10		$	3.92

« Previous Page 1 | 2 | 3 | 4 | 5 | 6 | 7 Next Page »